[
  {
    "doc_id": "NCT06424236",
    "population": ["participants with an Alzheimer's disease-causing mutation"],
    "intervention": ["gantenerumab"],
    "comparator": ["placebo", "solanezumab", "gantenerumab"],
    "outcome": ["Change From Baseline in Composite [11C] Pittsburgh Compound B (PiB)-Positron Emission Tomography (PET) Composite Standardized Uptake Value Ratio (C-SUVR) at Weeks 52, 104 and 156"]
  },
  {
    "doc_id": "NCT03131453",
    "population": ["cognitively unimpaired participants aged 60 to 75 years, with at least one apolipoprotein E allele (APOE4), (homozygotes (HMs) or heterozygotes (HTs)) and, if HTs, with evidence of elevated brain amyloid"],
    "intervention": ["CNP520 50 mg", "CNP520 15 mg"],
    "comparator": ["placebo"],
    "outcome": ["Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))"]
  },
  {
    "doc_id": "NCT05256134",
    "population": ["amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD"],
    "intervention": ["gantenerumab"],
    "comparator": ["placebo"],
    "outcome": ["Change From Baseline in PACC-5 Score"]
  },
  {
    "doc_id": "NCT02565511",
    "population": ["cognitively unimpaired APOE4 homozygotes (HMs) aged 60 to 75 years"],
    "intervention": ["CAD106 Immunotherapy","CNP520","Alum"],
    "comparator": ["placebo"],
    "outcome": ["Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))"]
  },
  {
    "doc_id": "NCT04408755",
    "population": ["participants with a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD"],
    "intervention": ["AVP-786"],
    "comparator": ["placebo"],
    "outcome": ["Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score"]
  },
  {
    "doc_id": "NCT04464564",
    "population": ["participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD"],
    "intervention": ["AVP-786"],
    "comparator": ["placebo"],
    "outcome": ["Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation"]
  },
  {
    "doc_id": "NCT03814382",
    "population": ["adults with a diagnosis of cognitively unimpaired, or probable Alzheimer's Disease, Frontotemporal Dementia or Dementia with Lewy Bodies"],
    "intervention": ["Acupuncture"],
    "comparator": [],
    "outcome": ["Heart Rate Variability as Measured by BioStamp","Galvanic Skin Response"]
  },
  {
    "doc_id": "NCT02769000",
    "population": ["patients with early Alzheimer's dementia"],
    "intervention": ["Radiation: 10 GY", "Radiation: 20 GY"],
    "comparator": [],
    "outcome": ["CTCAE toxicity grading"]
  },
  {
    "doc_id": "NCT06677203",
    "population": ["adult participants with early Alzheimer's disease"],
    "intervention": ["ASN51"],
    "comparator": ["placebo"],
    "outcome": ["Number of Participants With Adverse Events (AEs)", "Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)"]
  },
  {
    "doc_id": "NCT02791191",
    "population": ["participants with mild Alzheimer's disease (AD) dementia"],
    "intervention": ["LY3202626"],
    "comparator": ["placebo"],
    "outcome": ["Change From Baseline in F-AV-1451 Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) at 52 Weeks"]
  },
  {
    "doc_id": "NCT02972658",
    "population": ["participants with early Alzheimer's disease dementia"],
    "intervention": ["Lanabecestat"],
    "comparator": [],
    "outcome": ["Change From Baseline Analysis on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)"]
  },
  {
    "doc_id": "NCT00676143",
    "population": ["patients with mild to moderate Alzheimer Disease"],
    "intervention": ["bapineuzumab"],
    "comparator": ["placebo"],
    "outcome": ["Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78"]
  },
  {
    "doc_id": "NCT00667810",
    "population": ["patients with mild to moderate Alzheimer Disease"],
    "intervention": ["bapineuzumab"],
    "comparator": ["placebo"],
    "outcome": ["The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78"]
  },
  {
    "doc_id": "NCT01561430",
    "population": ["participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque"],
    "intervention": ["LY2886721"],
    "comparator": ["Placebo"],
    "outcome": ["Change From Baseline to 12 Weeks in Cerebrospinal Fluid (CSF) Amyloid Beta (Aβ)1-40 and Aβ1-42 Concentrations","Change From Baseline to 26 Weeks in CSF Aβ1-40 and Aβ1-42 Concentrations"]
  },
  {
    "doc_id": "NCT02783573",
    "population": ["participants with mild Alzheimer's disease (AD) dementia"],
    "intervention": ["Lanabecestat"],
    "comparator": ["Placebo"],
    "outcome": ["Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog13) Score"]
  },
  {
    "doc_id": "NCT02884492",
    "population": ["elderly subjects with different clinical and biomarker profiles of Alzheimer's disease (AD)"],
    "intervention": ["18F-THK-5351"],
    "comparator": [],
    "outcome": ["18F-THK-5351 Standardized Uptake Value Ratio"]
  },
  {
    "doc_id": "NCT05602727",
    "population": ["participants with mild to moderate Alzheimer's Disease (AD) dementia"],
    "intervention": ["MK-1942"],
    "comparator": ["Placebo"],
    "outcome": ["Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Score at Week 12", "Number of Participants Experiencing an Adverse Event (AE)", "Number of Participants Discontinuing Study Medication Due to an Adverse Event"]
  },
  {
    "doc_id": "NCT03289143",
    "population": ["participants with prodromal to mild Alzheimer's disease"],
    "intervention": ["Semorinemab", "[18F]GTP1"],
    "comparator": ["Placebo"],
    "outcome": ["Change From Baseline on the CDR-SB", "Percentage of Participants With Adverse Events", "Change From Baseline on the C-SSRS", "Other Abnormal MRI Findings"]
  },
  {
    "doc_id": "NCT03491150",
    "population": ["participants who complete Study BN29552 or BN29553"],
    "intervention": ["Crenezumab"],
    "comparator": [],
    "outcome": ["Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "Percentage of Participants With Anti-Crenezumab Antibodies"]
  },
  {
    "doc_id": "NCT01900665",
    "population": ["participants with mild AD"],
    "intervention": ["Solanezumab"],
    "comparator": ["Placebo"],
    "outcome": ["Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)"]
  }
]

